| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64796SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2219SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-205 | |||
| BSA Free | NB500-205SS | |||
| BSA Free | NB500-238SS | |||
| Azide and BSA Free | NBP2-80969 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-74340SS | |||
| Azide and BSA Free | NBP2-80561 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-540SS | |||
| Azide and BSA Free | NBP2-80677 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-13173SS | |||
| Azide and BSA Free | NBP2-80855 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB600-1008SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1475SS | |||
| Azide and BSA Free | NBP2-80640 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-428SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-266SS | |||
| Azide and BSA Free | NBP2-80869 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1071SS | |||
| Azide and BSA Free | NBP2-80642 | |||
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat brain cryosection with Mouse.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Frozen-NB100-64796-img0012.jpg "Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat brain cryosection with Mouse.")
![Flow Cytometry: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the Alexa Fluor (R) 488 conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of PBMC's (Monocyte gate at 1 x 10^6 cells/ml) with CD31 antibody (orange) stained at a dilution of 1:500. Shown with mIgG (AF488) isotype control (blue).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Flow-Cytometry-NB100-64796-img0007.jpg)
![Immunohistochemistry-Paraffin: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis of CD31 in 4th day cutaneous wound section of diabetic rat using CD31/PECAM-1 Antibody (TLD-3A12). Image from verified customer review.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Paraffin-NB100-64796-img0005.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat spleen cryosection.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Frozen-NB100-64796-img0013.jpg)
![Immunohistochemistry-Paraffin: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - IHC analysis for the expression of CD31 of wound tissues of different groups of rats (magnification 200). n = 6, **P less than 0.01. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/sci/2019/9564869/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Paraffin-NB100-64796-img0014.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0015.jpg "Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - In vitro analysis of PHD-2 knockout and protein quantification.Western blot data for PHD-2 knockout in fibroblasts of heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). D') Western blot data for PHD-2 knockout in keratinocytes of heterozygous K14-Cre/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Knockdown-Validated-NB100-2219-img0016.jpg)
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of an FFPE mouse lung section using 1:200 dilution of EGLN1/PHD2 antibody. The staining was developed using HRP conjugated anti-rabbit secondary antibody and DAB reagent. The antibody generated a specific staining in the cytoplasm and nuclei of alveolar as well as bronchiolar epithelial cells. Cytoplasmic staining was observed in almost all cells while the nuclear positivity was seen in a subset of cells only.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-Paraffin-NB100-2219-img0014.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - Detection of EGLN1/PHD2 in mouse kidney lysate. ECL exposure, 20 seconds.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-2219-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - EGLN1/PHD2 antibody at 1:500 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of EGLN1/PHD2 in ARPE-19 cells using anti-PHD2 antibody. ICC/IF image submitted by a veriifed customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0009.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - Staining of renal tubular epithelium in mouse using NB100-2219 at 2.5 ug/mL.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0010.jpg)
![Immunohistochemistry: Survivin Antibody (60.11) [NB500-238] - Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein (A). High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable (B). Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining (C and D). For A and B the polyclonal rabbit anti-survivin antibody [AF886] was used. For C and D the monoclonal mouse Survivin Antibody (60.11) [NB500-238] was used. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Immunohistochemistry-NB500-238-img0019.jpg "<b>Independent Antibodies Validation. </b>Immunohistochemistry: Survivin Antibody (60.11) [NB500-238] - Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein (A). High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable (B). Other specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining (C and D). For A and B the polyclonal rabbit anti-survivin antibody [AF886] was used. For C and D the monoclonal mouse Survivin Antibody (60.11) [NB500-238] was used. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license.")
![<b>Independent Antibodies Validation. </b>Flow (Intracellular): Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on A549 cells with Survivin Antibody (60.11) [NB500-238] and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems). Image using the Unpurified form of this antibody.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Flow-Intracellular-NB500-238-img0015.jpg)
![Western Blot: Survivin Antibody (60.11) [NB500-238] - Survivin detection in 30ug of HeLa whole cell extract using [NB500-238] at 1ug/ml. Detected at predicted molecular weight of 16 kDa.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Western-Blot-NB500-238-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: Survivin Antibody (60.11) [NB500-238] - Knockdown Validation of Survivin Antibody (60.11) [NB500-238]. Suppression of survivin expression by transfection of siRNA. RNA interference was performed in SW1353 and Hs 819.T, either for GFP as control or for survivin. A: A pronounced decrease of survivin protein levels was measured by immunoblotting in SW1353 and Hs819.T. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-120), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Knockdown-Validated-NB500-238-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: Survivin Antibody (60.11) [NB500-238] - HeLa cells stained NB500-205 (Green) detected with DyLight Fluor 488 conjugated anti-mouse IgG secondary antibody. Nuclei are counterstained with Hoechst 33258 (Blue). Image using the Unpurified format of this antibody.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Immunocytochemistry-Immunofluorescence-NB500-238-img0021.jpg)
![Immunohistochemistry-Paraffin: Survivin Antibody (60.11) [NB500-238] - Staining of ovary cancer. Image using the Unpurified format of this antibody.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Immunohistochemistry-Paraffin-NB500-238-img0022.jpg)
![Flow Cytometry: Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on U2OS cells with Survivin Antibody (60.11) [NB500-238AF700] (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Flow-Cytometry-NB500-238-img0017.jpg)
![Flow (Intracellular): Survivin Antibody (60.11) [NB500-238] - An intracellular stain was performed on Daudi cells with Survivin Antibody (60.11)[NB500-238] (blue) and a matched isotype control, Mouse IgG2a Kappa Light Chain Isotype Control (MG2a-53) [NB600-986] (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/Survivin-Antibody-60-11-Flow-Intracellular-NB500-238-img0014.jpg)
![Western Blot: Survivin Antibody (60.11) - BSA Free [NB500-238] - Binding of antibody (60.11) used in imaging flow cytometry to full-length survivin protein & to survivin vaccine peptide aa53-67/M57 & wild type peptide aa53-67 Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.21773), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-238_mouse-monoclonal-survivin-antibody-60-11-31020241539726.jpg)
![Western Blot: Survivin Antibody (60.11) - BSA Free [NB500-238] - CD133+ cells are more resistant to chemotherapeutic agents. STA-ET-8.2 cells were FACS-sorted & CD133+ & CD133- fractions treated with increasing concentrations of (A) Doxorubicin (Doxo), (B) Etoposide (Etop), (C) Vincristine (Vinc) or (D) a combination of all three drugs at high (Doxo 10 μM; Etop 10 ug/ml; Vinc 100 ng/ml), medium (Doxo 2.5 μM; 20 Etop 2.5 ug/ml; Vinc 25 ng/ml) & low (Doxo 0.5 μM; Etop 0.5 ug/ml; Vinc5 ng/ml) concentrations. Viability was assessed by MTS assay after 96 hrs (*p < 0.05) & CD133+ cells displayed increased drug resistance. (E): CD133+ & CD133- TC-71 cells are equally sensitive to Doxo, Etop, & Vinc. (F): Western blot reveals no difference in apoptosis & drug resistance protein expression between unsorted & CD133-sorted STA-ET-8.2 cell fractions. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/20346143), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-238_mouse-monoclonal-survivin-antibody-60-11-310202416163762.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Total protein from HeLa, 3T3, PC12 and Bovine normal tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/mL anti-Actin in 5% blocking buffer and detected with an anti-mouse IgM secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Western-Blot-NB100-74340-img0019.jpg "Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Total protein from HeLa, 3T3, PC12 and Bovine normal tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/mL anti-Actin in 5% blocking buffer and detected with an anti-mouse IgM secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: Actin Antibody (mAbGEa) [NB100-74340] - NIH-3T3 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-Actin (mAbGEa) at 5 ug/mL overnight at 4C and detected with an anti-Mouse IgM DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunocytochemistry-Immunofluorescence-NB100-74340-img0018.jpg)
![Simple Western: Actin Antibody (mAbGEa) [NB100-74340] - Image shows a specific band for Actin in 0.1 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Simple-Western-NB100-74340-img0014.jpg)
![Immunohistochemistry-Paraffin: Actin Antibody (mAbGEa) [NB100-74340] - Both normal and cancer biopsies of deparaffinized Human tonsil tissues.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunohistochemistry-Paraffin-NB100-74340-img0005.jpg)
![Flow Cytometry: Actin Antibody (mAbGEa) [NB100-74340] - Analysis of HeLa cells using mouse Actin antibody (Orange) and Isotype control Antibody (Blue).](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Flow-Cytometry-NB100-74340-img0015.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Increased relative abundance of Park7 in Lp(a) mice. Western blots were used to validate the comparative proteomic analysis between the Lp(a) and wildtype mice for the Park7 protein. Pooled liver protein extracts (n = 4 livers per pool) were separated by SDS PAGE in multiple replicates (n = 7) and transferred onto nitrocellulose membrane. Membranes were probed with an anti-Park7 antibody using an anti-actin antibody as a loading control. Liver protein extracts were the same as those used for Figure 4(a) as well as fresh liver protein extracts from new mice of the same age, sex, and genotype. Image collected and cropped by CiteAb from the following publication (null), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Western-Blot-NB100-74340-img0022.jpg)
![Immunocytochemistry/Immunofluorescence: Actin Antibody (mAbGEa) [NB100-74340] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-Actin Antibody (mAbGEa) at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunocytochemistry-Immunofluorescence-NB100-74340-img0021.jpg)
![Flow (Intracellular): Actin Antibody (mAbGEa) [NB100-74340] - An intracellular stain was performed on A549 cells with NB100-74340 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse IgM Alexa Fluor 488-conjugated secondary antibody.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Flow-Intracellular-NB100-74340-img0020.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Analysis of Actin expression in 2) HeLa, 3) NTERA-2, 4) A431, 5) HepG2, 6) MCF7, 7) NIH-3T3, 8) PC-12 and 9) COS-7 whole cell lysates.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Western-Blot-NB100-74340-img0008.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Analysis of Jurkat and CHO cell lysates using actin antibody [NB100-74340] at 1:100.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Western-Blot-NB100-74340-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: Actin Antibody (mAbGEa) [NB100-74340] - Actin was detected in NIH-3T3 cells fixed with methanol using mouse anti-mouse beta-Actin monoclonal antibody (NB100-74340) at 1:1800. Cells were stained using Northern Lights 557 conjugated anti-mouse secondary antibody (NL007) and counterstained with DAPI.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunocytochemistry-Immunofluorescence-NB100-74340-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: Actin Antibody (mAbGEa) [NB100-74340] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-Actin (mAbGEa) at 2 ug/mL overnight at 4C and detected with an anti-mouse IgM DyLight 488 (Green) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunocytochemistry-Immunofluorescence-NB100-74340-img0017.jpg)
![Immunohistochemistry-Paraffin: Actin Antibody (mAbGEa) [NB100-74340] - Analysis of Actin on human breast cancer tissue using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunohistochemistry-Paraffin-NB100-74340-img0010.jpg)
![Immunohistochemistry-Paraffin: Actin Antibody (mAbGEa) [NB100-74340] - Both normal and cancer biopsies of deparaffinized Human colon carcinoma tissues.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunohistochemistry-Paraffin-NB100-74340-img0003.jpg)
![Immunohistochemistry-Paraffin: Actin Antibody (mAbGEa) [NB100-74340] - Both normal and cancer biopsies of deparaffinized Human skeletal muscle tissues.](http://images.novusbio.com/fullsize/Actin-Antibody-mAbGEa-Immunohistochemistry-Paraffin-NB100-74340-img0004.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Lp(a) upregulates GPx1 & Prdx6 expression in human HepG2 cells. HepG2 cells were treated with 5 μg/mL of Lp(a) or LDL for 6 hours at 37°C. Western blots of cell lysates were performed with an anti-Gpx1 antibody (a), an anti-Prdx6 antibody (b), an anti-Sod1 antibody (c), & an anti-Park7 antibody (d) using an anti-actin antibody as a loading control. Representative blots are shown. Protein levels were normalized against actin & expressed relative to that of untreated cells. Results are expressed as mean ± SEM for pooled triplicate incubations run in quadruplicate. ∗P<0.05, relative to untreated HepG2 cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30596094), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-310202415392542.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - DenA deneddylase activity.(A) Recombinant human DEN1 & fungal DenA deneddylate a human CUL1-Nedd8 substrate in vitro. SDS-PAGE & subsequent western analysis show cleavage of the substrate (∼60 kDa) producing the C-terminal CUL1 (∼50 kDa) as outlined in experimental procedures. (B) Deneddylation test in a heterologous yeast system. A. nidulans DenA can remove Rub1 from CulD in heterologous expression experiments in S. cerevisiae. DenA expressed as native protein or C-terminally fused w/ a V5/His6 epitope tag. Both variants driven by the inducible GAL1 promoter. CulD, N-terminal-fused w/ the LexA activation domain, expressed under control of the constitutive ADH promoter. A. nidulans proteins expressed in S. cerevisiae wild type & delta csn5 background. Western analysis w/ antibodies against Rub1 ( alpha -Rub1), the LexA epitope ( alpha -LexA) & the V5 epitope ( alpha -V5) performed. Detection w/ alpha -Rub1 generated two additional signals upon culD expression, representing LexA-CulD & a second CulD pool where LexA unspecifically cleaved off. Both signals disappeared upon co-expression of DenA indicating deneddylation activity (red arrows). The slower migrating signal of alpha -LexA western experiments corresponded to Rub1 modified LexA-CulD. This signal absent when DenA co-expressed. Detection of the V5 tag applied to monitor DenA expression. The neddylated yeast cullin migrating at around 100 kDa not affected by DenA activity. (C) Deneddylation of fungal CulA by CSN & DenA. Whole cell lysates of A. nidulans wild type, delta csnE & delta denA probed w/ alpha -CulA. The ratio of neddylated CulA (CulA*N8; ∼106 kDa*) to non-neddylated CulA (∼96 kDa**) calculated from three independent experiments. Membranes reprobed w/ alpha -Actin ( alpha -ACT) for normalization. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1003275), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-31020241682162.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Fibrillar adhesions & FN fibrils are dynamic structures governed by Rab21 & PPFIA1.(a) Living siCTL & siRAB21 ECs incubated w/ IST9 mAb for 30 min, fixed, acid washed & stained. RAB21 silencing impairs ED-A FN endocytosis as revealed by decrease of IST9 punctae co-localizing w/ endosome marker EEA1. Right panels are magnifications of boxed areas in left panels. Data are mean value±s.e.m., n=70 cells per condition pooled from two independent experiments. ***P<0.001. (b) Left panel, WB analysis of PPFIA1, RAB21 & actin on total lysates of siCTL, siPPFIA1 & siPPFIA1+siRAB21 ECs. Right panel, WB analysis of insoluble matrix fraction of ECs extracted w/ DOC buffer. PPFIA1 silencing dramatically reduces amount of DOC-insoluble fraction of endogenous ED-A FN. Of note, simultaneous silencing of Rab21 GTPase (siPPFIA1+siRAB21), which drives integrin endocytosis, rescues defective incorporation of endogenous ED-A FN in DOC-insoluble fraction of siPPFIA1 ECs. (c) Confocal microscopy analysis of patterning of endogenous cellular ED-A FN (green) in fixed confluent ECs. Before fixation, living ECs incubated for 20 min w/ exogenous SNAKA51 (red). ED-A FN polymerizes into a fibrillar network in siCTL, but not in siPPFIA1 ECs. Simultaneous silencing of Rab21 GTPase (siPPFIA1+siRAB21) fully restores ED-A FN polymerization in siPPFIA1 ECs. SNAKA51+ active alpha 5 beta 1 integrin localizes in fibrillar adhesion in siCTL, but not in siPPFIA1 ECs. Notably, simultaneous Rab21 (siPPFIA1+siRAB21) silencing promotes localization of SNAKA51 in fibrillar adhesion of siPPFIA1 ECs. Data are mean±s.e.m., n=20 cells per condition pooled from two independent experiments. Scale bar, 20 μm (a,c, right), 50μm (c, left). ***P<0.001; Student's t-test. Image collected & cropped by CiteAb from following publication (//www.nature.com/articles/ncomms13546), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-31020241554546.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Effect of the four most common herbal formulas & single herbs on the phosphorylation of myosin light chain (MLC) protein.Briefly, A10 cells were treated with herbal formulas (A) or single herbs (B). Y27632 (Y10; 10 μM) & calyculin A (A50; 50 μg/ml) were used as negative & positive controls. Western blot analysis & staining with anti-phospho-MLC, anti-total-MLC, & anti-beta actin antibodies was then performed. Phospho-MLC, total-MLC, & beta actin were all obtained with their appropriate protein size bands. The relative Phospho-MLC intensity (%) was expressed as [(Phospho-MLC/total-MLC)drug treated/ (Phospho-MLC/total-MLC)cell only x 100%]. The Mean±SEM values for at least three independent experiments along with the representative western blot were performed. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0145109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-310202415533828.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - CSN targets DEN1/DenA for degradation in fungal & human cells.(A) Quantitative analysis of repeated western blot experiments displayed the differences in DenA abundance in fungal wild type & delta csnG cells. DenA levels of the different asexual developmental time points are shown relative to the vegetative (veg.) control for each strain. Anti-Actin was applied as loading control (statistics: 2-way ANOVA; n = 3; *p<0,05, **p<0,01). (B) Xpress-DEN1 was overexpressed in siGFP & siCSN1 human cells & steady state Xpress-DEN1 levels were estimated by western analysis with the alpha -Xpress antibody. Xpress-CSN1 was overexpressed in siCSN1 cells & DEN1 & CSN8 were probed with appropriate antibodies. (C) Xpress-DEN1 was overexpressed in siGFP human cells & the proteasome inhibitor MG132 was added 6 h before cell lysis at a final concentration of 10 µM. Cyclohexamide (CHX) was added in a final concentration of 10 µg/ml (D) Xpress-DEN1 was co-expressed in HeLa cells together with Xpress-CSN1wt, Xpress-CSN1(1–221) or Xpress-CSN1(222–527) in the absence or in the presence of MG132 (right panel), which was added 6 h before cell lysis. Cells were lyzed 24 h after co-transfection & lysates were analyzed by western blot using the alpha -DEN1 antibody (0 = only Xpress-DEN1). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pgen.1003275), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-31020241682157.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Analysis of Ia production by engineered S. cerevisiae.(A) Analysis of the synthesis of Ia in S. cerevisiae strains, producing actin-R177K, E270D & E270Q. Yeast strains, producing actin-R177K, E270D or E270Q & transformed with the Ia-containing plasmid (Ia) or the vector alone (Vector), were cultivated in SGal for 20 h at 30°C. Cells were broken by glass beads treatment & analyzed by 32P-ADP-ribosylation in the presence of additionally added purified wild type yeast actin (1 μg). Labeled bands represent modified yeast actin & confirm intracellular production of functionally active Ia by the S. cerevisiae strains. (B) Production of Ia by the wild type S. cerevisiae strain. Wild type yeast strains harboring the Ia-containing plasmid (Ia) or the control vector (vector) were cultivated in glucose-containing liquid medium until OD595 = 0.5. Afterwards, glucose was replaced by galactose & cultivation continued for 9 h at 30°C. Cells were lysed & the resulting extract preparations were ADP-ribosylated in the presence of Ia (+ Ia), TccC3 toxin of P. luminescens [42] (+ TccC3), purified muscle actin (+ alpha -actin) or tested in Western blotting with the anti-actin serum to show equal actin concentrations in the samples. (C, D) Mass spectrometry of actin variants. MALDI-TOF MS of wild type (C) & actin-R177K (D) protein variants isolated from S. cerevisiae. Spectra demonstrate disappearance of R177- & appearance of K177-containing peptide in mass analysis (substituted amino acid residue within identified peptides is shown in red). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0145708), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-31020241612620.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - alpha 5 beta 1 regulates ED-A FN secretion & polymerization.(a) Western blot analysis of lysates of ECs control (siCTL) & alpha 5 integrin subunit (siITGA5) silenced ECs. Cells were lysed 24 hours after the second siRNA oligofection & proteins were separated by SDS–PAGE & probed for alpha 5 integrin subunit or actin (for control purposes). (b) Confocal microscopy analysis of IST9 mAb-labelled endogenous ED-A FN (green) in confluent ECs. ED-A FN polymerizes into a fibrillar network in siCTL, but not in siITGA5 ECs in which it accumulates in the TGN46+ (red) TGN cisternae. The relative amount of fibrillar ED-A FN area was calculated in siCTL & siITGA5 ECs. Data are mean±s.e.m., n=20 cells per condition pooled from two independent experiments. ***P<0.001; Student's t-test. (c) Western blot analysis of soluble ED-A FN released by confluent ECs seeded on Transwell inserts. An equal percentage of apical & basolateral volumes of medium were collected after 72 h of culture, from different wells of siCTL or siITGA5 ECs. Equal amounts of exogenous rabbit IgG were added to samples (spike normalization) for loading control purposes. Quantification of the ratio between apical or basolateral amount of ED-A FN released by siCTL over siITGA5 ECs. alpha 5 integrin subunit silencing impairs basolateral, but not apical ED-A FN secretion. Data are mean±s.e.m., n=8 wells per condition pooled from four independent experiments. **P<0.01; Student's t-test. Scale bar, 50 μm (b). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms13546), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-310202415535157.jpg)
![Western Blot: Actin Antibody (mAbGEa) [NB100-74340] - Effect of the four most common herbal formulas & single herbs on the phosphorylation of myosin light chain (MLC) protein.Briefly, A10 cells were treated with herbal formulas (A) or single herbs (B). Y27632 (Y10; 10 μM) & calyculin A (A50; 50 μg/ml) were used as negative & positive controls. Western blot analysis & staining with anti-phospho-MLC, anti-total-MLC, & anti-beta actin antibodies was then performed. Phospho-MLC, total-MLC, & beta actin were all obtained with their appropriate protein size bands. The relative Phospho-MLC intensity (%) was expressed as [(Phospho-MLC/total-MLC)drug treated/ (Phospho-MLC/total-MLC)cell only x 100%]. The Mean±SEM values for at least three independent experiments along with the representative western blot were performed. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0145109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74340_mouse-monoclonal-actin-antibody-mabgea-310202415533829.jpg)
![Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Intracellular-NB200-540-img0005.jpg "<b>Biological Strategies Validation. </b>Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Complement C3 Antibody (11H9) [NB200-540] - C3 protein fragments deposited on kidney cells of MPL-lpr mouse. Staining with antibody 11H9. Glomerular staining pattern. Fixation in 4% paraformaldehyde in PBS pH 7.4. Vibratome sections of 4 um. Pretreated with 3% hydrogen peroxide for 20 min to quench endogenous peroxidases. Microwaved in antigen unmasking solution for 2-5 minutes as antigen retrieval.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunocytochemistry-Immunofluorescence-NB200-540-img0002.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse liver using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. Weak but distinct membrane-cytoplasmic immunopositivity was observed in hepatocytes and few cells developed punctate membrane staining.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0004.jpg)
![Flow Cytometry: Complement C3 Antibody (11H9) [NB200-540] - Left panel: FMO, Middle panel: No primary antibody control, Right panel: sample. Day 6 murine mammary tumors processed and stained for analysis with flow cytometry. The C3b+ population of CD45+ cells is what the gate in each sample is exhibiting. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Cytometry-NB200-540-img0006.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse lymph node using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. This representative photomicrograph shows a membrane-cytoplasmic immunopositivity in non-germinal center cells, and few cells developed an intense staining for this target protein.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0003.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of activated MMP9 expression in MMP9 proenzyme incubated with trypsin for various times.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Western-Blot-NBP2-13173-img0002.jpg "Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of activated MMP9 expression in MMP9 proenzyme incubated with trypsin for various times.")
![Immunohistochemistry: MMP-9 Antibody (4A3) [NBP2-13173] - MMP-9 (green) was detected in murine brain (cortex) using MMP-9-DyLight 488 (4A3) with a concentration of 1:20 in PBS for 2 hours. MMP9-Signals are overlaped with the corresponding phase contrast image. Image from verified customer review. Image using the FITC format of this antibody.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Immunohistochemistry-NBP2-13173-img0006.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - Identification of gelatinases by Western blot analysis. A pool of sera from 10 patients with inactive RR-MS was used. For 2-DZ, pooled sera were concentrated 10-fold and 40 ug of total proteins were applied (left panels). For Western blot analysis pooled sera were concentrated 40-fold and 160 ug of total proteins were subjected to 2-DE (right panels). 2-DE gels were cut and the corresponding nitrocellulose membranes were treated with anti-NGAL Ab (A'), anti-MMP-2 Ab (B') and Anti-MMP-9 (4A3) Ab, recognizing the 65 kD and the 82 kD activated forms (C'); Gel C show the region with isoelectric point between pH 4-5.5 and molecular mass between 85 and 55 kD, analysed by Western blot in C', respectively. Image collected and cropped by CiteAb from the following publication (null), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Western-Blot-NBP2-13173-img0011.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 1-DZ analysis and identification of gelatinases by Western blot. 1.5 ul of serum from healthy control (HC) or from a patient with inactive RR-MS were loaded on a 7.5% polyacrylamide gel copolymerized with 0.1% (w/v) gelatin (1-DZ). For Western blot analysis, 2 ul of fivefold concentrated (Vivaspin 500, MWCO 50,000; GE Healthcare) serum samples (the same as in 1-DZ) were separated on a 7.5% polyacrylamide gel without gelatin (1-DE), transferred on nitrocellulose membranes and incubated with the following primary antibodies: Anti-NGAL Antibody (5G5) at concentration of 2.0 ug/ml; Anti-MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 ug/ml; Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7) at concentration of 1.0 ug/ml and Anti-MMP-9 Ab (4A3) at concentration of 2.0 ug/ml. Image collected and cropped by CiteAb from the following publication (null), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Western-Blot-NBP2-13173-img0012.jpg)
![Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of a FFPE tissue section of human esophageal cancer using MMP9 antibody (clone 4A3) at 1:200. The staining was developed with HRP-labelled secondary antibody and DAB reagent followed by hematoxylin counterstaining. This antibody generated a specific extracellular and cytoplasmic staining primarily in the cancer cells while the signal was pretty weak in the tumor stroma.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Immunohistochemistry-Paraffin-NBP2-13173-img0003.jpg)
![Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of a FFPE section of human esophageal cancer using MMP9 antibody (clone 4A3) at 1:200. The staining was developed with HRP-labelled secondary antibody and DAB reagent followed by hematoxylin counterstaining. This antibody clone generated an extracellular and cytoplasmic staining mainly in the cancer cells while the signal was very weak in the stromal cells of the tumor.](http://images.novusbio.com/fullsize/MMP-9-Antibody-4A3-Immunohistochemistry-Paraffin-NBP2-13173-img0004.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 2-DZ analysis & identification of MMP-9 by Western blot. Left panels (A & B): 2-D zymography (2-DZ) of serum samples from healthy control (A) & from an inactive RR-MS patient not subjected to therapy (same patient as in Fig. 2; B). For 2-DZ, aliquots of 35 μl of serum were resuspended in the rehydration solution & subjected to isoelectrofocusing (IEF; 1st dimension) on IPG Dry-Strips of 13 cm in a linear pH gradient of 4–7. After IEF, IPG strips were equilibrated & then applied for the 2nd dimension in a 8.5% (w/v) polyacrylamide gel copolymerized with 0.1% (w/v) gelatin. The isoforms & charge variants of MMP-2 & MMP-9 appear as clear spots of digestion on the dark background of the gel. Right panels (A' & B') represent Western blot analysis of the same sera shown in A & B. Aliquots of 35 μl of serum samples (instead of the usual 20 μl) were subjected to 2D electrophoresis (2-DE) by using 8.5% (w/v) polyacrylamide gels without gelatin. After transfer of the proteins, the nitrocellulose membranes were incubated with an anti MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 μg/ml. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24616914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13173_mouse-monoclonal-mmp-9-antibody-4a3-31020241612243.jpg)
![Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 2-DZ analysis & identification of MMP-9 by Western blot. Left panels (A & B): 2-D zymography (2-DZ) of serum samples from healthy control (A) & from an inactive RR-MS patient not subjected to therapy (same patient as in Fig. 2; B). For 2-DZ, aliquots of 35 μl of serum were resuspended in the rehydration solution & subjected to isoelectrofocusing (IEF; 1st dimension) on IPG Dry-Strips of 13 cm in a linear pH gradient of 4–7. After IEF, IPG strips were equilibrated & then applied for the 2nd dimension in a 8.5% (w/v) polyacrylamide gel copolymerized with 0.1% (w/v) gelatin. The isoforms & charge variants of MMP-2 & MMP-9 appear as clear spots of digestion on the dark background of the gel. Right panels (A' & B') represent Western blot analysis of the same sera shown in A & B. Aliquots of 35 μl of serum samples (instead of the usual 20 μl) were subjected to 2D electrophoresis (2-DE) by using 8.5% (w/v) polyacrylamide gels without gelatin. After transfer of the proteins, the nitrocellulose membranes were incubated with an anti MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 μg/ml. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24616914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13173_mouse-monoclonal-mmp-9-antibody-4a3-310202416114778.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction by CoCl2 on Caki-1 cell lysate. HIF-1 alpha antibody (H1alpha67) [NB100-105]. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0019.jpg "<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction by CoCl2 on Caki-1 cell lysate. HIF-1 alpha antibody (H1alpha67) [NB100-105]. Western blot image submitted by a verified customer review.")
![<b>Biological Strategies Validation. </b>Simple Western: HIF-1 alpha Antibody Pack [NB100-900WB] - Simple Western lane view shows a specific band for HIF-1 alpha in 0.5 mg/mL of hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. HIF-1 alpha Antibody [NB100-449].](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Simple-Western-NB100-900WB-img0018.jpg)
![Simple Western: HIF-1 alpha Antibody Pack [NB100-900WB] - Image shows a specific band for HIF-1 alpha in 0.2 mg/mL of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Simple-Western-NB100-900WB-img0022.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Naive CD4 T cells from WT, VHL-deficient (Vhl KO), or HIF-1 alpha-deficient (HIF-1 alpha KO) mice were differentiated under IL-22-skewing conditions for a total of 60 h. Some cells remained at normoxia for the duration of the culture (N); others were at normoxia for 35 h and then hypoxia (1% O2) for 24 h (H). At 60 h, nuclear extracts were harvested, and HIF-1 alpha and Lamin B1 levels were analyzed by Western blot. Image from verified customer review. HIF-1 alpha Antibody (H1alpha67) [NB100-105]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Knockout-Validated-NB100-900WB-img0020.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Normoxic pre-treatment sensitizes glioma cells to radiation after graded chronic hypoxic (GCH) exposure. The results of anchorage-independent colony forming assays are shown for U87, U87-luc, GL261 glioma cells and 0308 GSCs after 5 Gy radiation exposure under varying O2 conditions. For easier comparisons among cell types, raw values are expressed as a % of the cell type's negative (non-irradiated) control and the means & SEMs are plotted. Also shown are Western blots of nuclear HIF-1alpha at the time of irradiation. Corresponding Western blots of lamin A/C are shown as a loading control. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0111199) licensed under a CC-BY license. HIF-1 alpha Antibody [NB100-479]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0015.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Morphological alterations induced by DMOG are HIF-1alpha dependent. glEND.2 cells were stably transfected with shGFP, shHIF-1alpha or shHIF-2alpha. The clones were cultured under normoxic (N) or hypoxic (H, 1% O2) conditions, or treated with DMOG for 6 h. 30 ug protein of cellular protein were loaded for the detection of HIF-1alpha, and nuclear extracts (20 ug protein) were used for the detection of HIF-2alpha. Image collected and cropped by CiteAb from the following publication (//biosignaling.biomedcentral.com/articles/10.1186/1478-811X-11-80) licensed under a CC-BY license. HIF-1 alpha Antibody [NB100-449]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Knockdown-Validated-NB100-900WB-img0017.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Analysis of HIF-1 alpha in overexpression and endogenous HIF-1 alpha & HIF-2 alpha using anti-HIF-1 alpha antibody NB100-134. The data showed that HIF-1 alpha antibody did not react to HIF-2 alpha overexpression. Wester blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0021.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction on Caki-1 cell lysate using CoCl2. Western blot image submitted by a verified customer review. HIF-1 alpha Antibody [NB100-449]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0016.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Detection of HIF-1 alpha (125-130 kDa) from human placental villous explant total protein. HIF-1 alpha Antibody (HA111) [NB100-296]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0023.jpg)
![Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB600-1008] - Positive staining for Lyve-1 on FFPE Mouse Liver, 20x magnification. Antibody diluted 1:800. Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-Paraffin-NB600-1008-img0050.jpg "Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB600-1008] - Positive staining for Lyve-1 on FFPE Mouse Liver, 20x magnification. Antibody diluted 1:800. Image from verified customer review.")
![Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB600-1008] - Mouse kidney stained with LYVE-1 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-Paraffin-NB600-1008-img0047.jpg)
![Western Blot: LYVE-1 Antibody [NB600-1008] - Analysis of anti-mouse LYVE-1. Sample was loaded in 15% SDS-polyacrylamide gel under reducing conditions.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB600-1008-img0030.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB600-1008] - Zeb1-regulation of alkali-induced corneal NV in mice. c1 A representative stereoscopic image of the Zeb1-/+ and d1 Zeb1+/+ corneas and c2-d2 their whole flat-mount corneas immunostained with the endothelium marker CD31 and the lymphatic vessel marker LYVE-1. *p = 0.05; **p = 0.01. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32620870/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LYVE-1 Antibody-Immunohistochemistry-NB600-1008-img0057.jpg)
![Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB600-1008] - Mouse liver. Antibody at 1:800. Detection by Polymer-HRP. Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-Paraffin-NB600-1008-img0051.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB600-1008] - Hypoxia, blood vessel and proliferation staining. IHC staining in the Biopsy 23 and Biopsy 3 respectively for CA-9, EF5, CD31, Ki67 and LYVE1. 15x Magnification. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2072-6694/4/3/821), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB600-1008-img0052.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB600-1008] - Zeb1-regulation of alkali-induced corneal NV in mice.a Reduction of Zeb1 mRNA in the heterozygous Zeb−/+ corneas compared to the homozygous Zeb1+/+ corneas. b Significant NV score & vessel size reduction in the Zeb1−/+ corneas as compared to their Zeb1+/+ siblings. c1 A representative stereoscopic image of the Zeb1−/+ & d1 Zeb1+/+ corneas & c2–d2 their whole flat-mount corneas immunostained with the endothelium marker CD31 & the lymphatic vessel marker LYVE-1. *p ≤ 0.05; **p ≤ 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32620870), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1008_rabbit-polyclonal-lyve-1-antibody-31020241535663.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB600-1008] - Zeb1-regulation of alkali-induced corneal NV in mice.a Reduction of Zeb1 mRNA in the heterozygous Zeb−/+ corneas compared to the homozygous Zeb1+/+ corneas. b Significant NV score & vessel size reduction in the Zeb1−/+ corneas as compared to their Zeb1+/+ siblings. c1 A representative stereoscopic image of the Zeb1−/+ & d1 Zeb1+/+ corneas & c2–d2 their whole flat-mount corneas immunostained with the endothelium marker CD31 & the lymphatic vessel marker LYVE-1. *p ≤ 0.05; **p ≤ 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32620870), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1008_rabbit-polyclonal-lyve-1-antibody-310202415175280.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] (NB600-1475) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0019.jpg "Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] (NB600-1475) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - 4T1 tumor sections were stained for CD31 (green) and CD105 (red).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunohistochemistry-Frozen-NB600-1475-img0006.jpg)
![Flow (Cell Surface): CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on WEHI-3 Cells with CD31/PECAM-1 Antibody (MEC13.3) (NB600-1475, blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature, followed by rat F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0113, R&D Systems).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cell-Surface-NB600-1475-img0009.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - C57BL/6 mouse splenocytes stained with purified CD31/PECAM-1 Antibody (MEC13.3), followed by anti-rat IgG FITC](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] conjugated to DyLight 488 (NB600-1475G) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - MS1 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with at 5.0 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - was tested in Wehi-3 cells with Dylight 488 (green). Nuclei and beta-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0011.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - JAK3 colocalized with endothelial cells labeled with CD31. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fneur.2017.00363/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunohistochemistry-Paraffin-NB600-1475-img0015.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS1 cells with CD31/PECAM-1 [MEC13.3] Antibody NB600-1475R (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0022.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] conjugated to Alexa Fluor 647 (NB600-1475AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] conjugated to DyLight 550 (NB600-1475R) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0018.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Staining of mouse CD31 in non-small cell lung cancer tumor sections from a human NSCLC tumor-bearing mouse. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunohistochemistry-Frozen-NB600-1475-img0012.jpg)
![Flow (Cell Surface): CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on WEHI-3 Cells with CD31 (MEC13.3) antibody NB600-1475 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature, followed by rat F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0113, R&D Systems).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cell-Surface-NB600-1475-img0013.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS-1 cells with CD31/PECAM-1 Antibody (MEC13.3) (NB600-1475AF647, blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0014.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS1 cells with CD31/PECAM-1 [MEC13.3] Antibody NB600-1475DL594 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 594.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0020.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS1 cells with CD31/PECAM-1 [MEC13.3] Antibody NB600-1475G (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0021.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) - BSA Free [NB600-1475] - (A) Representative Western blots depicting phosphorylated JAK3 (pJAK3), total JAK3, & corresponding beta -actin levels in the ipsilateral (CXI) versus the contralateral (CXC) cortex at 24 h in sham & mice subjected to permanent middle cerebral artery occlusion (pMCAO). (B,C) Quantified pJAK3 & JAK3 values normalized to beta -actin in the cortex of sham & mice subjected to stroke. Both pJAK3 & JAK3 are significantly increased in the ipsilateral cortex of stroked animals (*P < 0.05 & **P < 0.01 with respect to sham ipsilateral/contralateral & stroke contralateral; sham, n = 5; stroke, n = 13). Data were analyzed using a two-way ANOVA (ipsilateral/contralateral or sham/stroke) with Bonferroni post-test. (D) Diagram showing peri-infarct brain region from which images were taken (n = 3). Scale bar is 10 µm, & magnification is 60×. (E) JAK3 colocalized with microglia/macrophages labeled with Iba-1. (F) JAK3 colocalized with neurons labeled with NeuN. (G) JAK3 colocalized with endothelial cells labeled with CD31. (H) JAK3 is not colocalized with astrocytes labeled with GFAP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28790974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1475_rat-monoclonal-cd31-pecam-1-antibody-mec13-3-310202416171428.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0007.jpg "Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.")
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Representative picture of western blot in histopathologically unchanged tissue (N) and primary cancerous tissue (C) from patients with CRC. Immunodetection of bands was performed with Rp anti- PHD1 (Catalog # NB100-310), - PHD2 (Catalog # NB100-137), - PHD3 (Catalog # NB100-139) and -FIH-1/HIF-1AN Ab (Catalog # NB100-139), followed by incubation with goat anti-rabbit HRP-conjugated Ab. The membrane was stripped and incubated with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-526), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0010.jpg)
![Immunohistochemistry: FIH-1/HIF-1AN Antibody [NB100-428] - Detection of FIH-1 in rat brain tissue.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Immunohistochemistry-NB100-428-img0008.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Rat VSMC (vascular smoot muscle) cells treated (siFIH) or not (CTL) with a specific siRNA against FIH-1. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - (C) Cytoplasmic FIH-1 (lower band) and MMP14 expression levels in both aerobic and hypoxic conditions in the 3 cell lines. (E) siRNA targeting FIH-1 was used to assess whether FIH-1 had any effect on CAIX expression in MCF-7 cells cultured in 0.5% O2 conditions. cont, control. m, transfection reagent alone. scr, scrambled siRNA. pool, mixture of 4 siRNAs targeting FIH-1. 21, single siRNA targeting FIH-1. (F) FIH-1 and CAIX expression levels in aerobic MCF-7 cells treated with either siRNA against FIH-1 alone, or both 400 uM CoCl2 and siRNA together for 24, 48 and 72h. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28476026/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN Antibody-Knockdown Validated-NB100-428-img0011.jpg)
![Immunohistochemistry: FIH-1/HIF-1AN Antibody [NB100-428] - 3D target protein expression in multicellular tumor spheroids3D expression analysis was carried out in the MCF-7, MDA-MB-231 & HBL-100 cell lines using multicellular tumor spheroids. The spheroids were cultured in spinner flasks for 1 week before fixation. Hypoxyprobe was used to examine the formation of hypoxic areas within the spheroids. NHE1, CAIX, MMP14 & FIH-1 expression was also analyzed. Incubation for an hour with PBS instead of primary antibody acted as a control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17143), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-428_rabbit-polyclonal-fih-1-hif-1an-antibody-310202415384122.jpg)
![Immunohistochemistry: Nestin Antibody (10C2) [NB300-266] - GFAP and Nestin immunoreactivity in retinal sections.Epifluorescent acquisition of p28 Reeler and WT retinas. (A-D) As compared to WT, both GFAP (red) and Nestin (green) immunoreactivities were highly visible in Reeler retinas (AB, GCL). Arrows point at yellow immunoreactivity in the white frame (B) indicating GFAP and Nestin co-expression in cells having long-filaments (activated Muller cells), as compared to wild type (arrowheads in A). Nuclei were DAPI counterstained (blue). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0212732) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Immunohistochemistry-NB300-266-img0020.jpg "Immunohistochemistry: Nestin Antibody (10C2) [NB300-266] - GFAP and Nestin immunoreactivity in retinal sections.Epifluorescent acquisition of p28 Reeler and WT retinas. (A-D) As compared to WT, both GFAP (red) and Nestin (green) immunoreactivities were highly visible in Reeler retinas (AB, GCL). Arrows point at yellow immunoreactivity in the white frame (B) indicating GFAP and Nestin co-expression in cells having long-filaments (activated Muller cells), as compared to wild type (arrowheads in A). Nuclei were DAPI counterstained (blue). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0212732) licensed under a CC-BY license.")
![Western Blot: Nestin Antibody (10C2) [NB300-266] - WB analysis of 5 ug lysate from (1) Rat's total brain tissue, and (2) human CNS progenitor cells using Nestin antibody (clone 10C2) at 1:1000 dilution. The antibody did not react with rat, whereas, in lysate from human samples, it generated a doublet band representing the phosphorylated and the non-phosphorylated forms of Nestin protein.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Western-Blot-NB300-266-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: Nestin Antibody (10C2) [NB300-266] - Analysis of formalin fixed, 0.1% Triton X-100 permeabilized F9 cells (Mouse teratocarcinoma) using Nestin antibody (clone 10C2) at 1:50 dilution. The primary antibody was detected using Alexa Fluor 488 labeled donkey anti-mouse IgG (H+L) cross-adsorbed secondary antibody (green) and nuclei were counterstained with DAPI (blue). An isotype control set was inclubated with mouse IgG1 isotype control antibody and the above mentioned secondary antibody. Nestin antibody (clone 10C2) generated a specific membrane-cytoplasmic staining of Nestin while the isotype control samples did not show any staining under same assay conditions.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Immunocytochemistry-Immunofluorescence-NB300-266-img0015.jpg)
![Immunohistochemistry-Paraffin: Nestin Antibody (10C2) [NB300-266] - Nestin was detected in immersion fixed paraffin-embedded sections of human kidney using anti-human mouse monoclonal antibody (Catalog # NB300-266) at 1:500 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Immunohistochemistry-Paraffin-NB300-266-img0013.jpg)
![Flow Cytometry: Nestin Antibody (10C2) [NB300-266] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using Nestin antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1 x 10^6 cells was used.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Flow-Cytometry-NB300-266-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: Nestin Antibody (10C2) [NB300-266] - Visualization of Nestin in PC-3 cells using NB300-266. Courtesy of Dolnick Lab, Roswell Park Cancer Institute.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Immunocytochemistry-Immunofluorescence-NB300-266-img0006.jpg)
![Flow Cytometry: Nestin Antibody (10C2) [NB300-266] - An intracellular stain was performed on SH-SY5Y cells with Nestin [10C2] Antibody NB300-266C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Flow-Cytometry-NB300-266-img0017.jpg)
![Flow Cytometry: Nestin Antibody (10C2) [NB300-266] - An intracellular stain was performed on HeLa cells with Nestin Antibody (10C2)NB300-266PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/Nestin-Antibody-10C2-Flow-Cytometry-NB300-266-img0016.jpg)
![Immunohistochemistry: Nestin Antibody (10C2) - BSA Free [NB300-266] - Regorafenib inhibits tumour growth and vascularisation in xenograft mice. GC1 were implanted into the right forebrain of mice. The mice then received daily oral vehicle or regorafenib at 30 mg/kg for 45 days. Representative photographs of mice brain tumours treated with regorafenib (right panel) or without regorafenib (left panel) stained by hemalun-eosin (median panel) or with nestin antibody (upper and lower panel). The upper panel shows whole brains of mice stained with nestin antibody. The tumour areas were circled in blue, and each surface was measured in mm^2. The red rectangles indicate the zone of the tumour shown in median (hemalun-eosin staining) and lower (nestin IHC) panel. Scale bars, upper panel 2.5 mm, median and lower panel 100 um. The graph shows the tumour size in mm^2 (expressed as the mean +/- SEM of 4 mice). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35326702/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nb300-266_mouse-monoclonal-nestin-antibody-10c2-20920231412574.jpg)
![Immunohistochemistry: Nestin Antibody (10C2) - BSA Free [NB300-266] - Regorafenib inhibits tumour growth & vascularisation in xenograft mice. GC1 were implanted into the right forebrain of mice. The mice then received daily oral vehicle or regorafenib at 30 mg/kg for 45 days. (A) Representative photographs of mice brain tumours treated with regorafenib (right panel) or without regorafenib (left panel) stained by hemalun–eosin (median panel) or with nestin antibody (upper & lower panel). The upper panel shows whole brains of mice stained with nestin antibody. The tumour areas were circled in blue, & each surface was measured in mm2. The red rectangles indicate the zone of the tumour shown in median (hemalun–eosin staining) & lower (nestin IHC) panel. Scale bars, upper panel 2.5 mm, median & lower panel 100 µm. The graph shows the tumour size in mm2 (expressed as the mean ± SEM of 4 mice). (B) Representative immunohistochemistry photographs of CD31+ vessels in brain tumour areas of 3 different mice treated with regorafenib (right panel) or without regorafenib (control, left panel). Arrows indicate CD31+ blood vessels. Scale bars, 20 µm. The graph shows the number of CD31+ vessels in tumours per mm2 (expressed as mean ± SEM of 4 mice). * p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35326702), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-266_mouse-monoclonal-nestin-antibody-10c2-310202416212379.jpg)
![Immunocytochemistry/Immunofluorescence: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 antibody was tested in WEHI-3 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunocytochemistry-Immunofluorescence-NB600-1071-img0003.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse small intestine using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. This antibody specifically labelled the endothelial cells in blood vessels located primarily in the sub-mucosa, and of that of the mucosa muscularis and the mucosal lacteal.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0014.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 (MEC 14.7) antibody was tested at 1:250 in WEHI-3 cells with DyLight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0002.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of CD34 on human renal cancer xenograft using CD34 antibody (clone MEC 14.7). The antibody detected the endothelial cells in the tumor vasculature which are originating from the host (mouse).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0005.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a human renal cancer tissue section using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The antibody did not detect human CD34 which is an expected outcome for this clone. This section was included in NB600-1071's IHC validation testing as a negative control.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0006.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody clone MEC 14.7 at 1:100 dilution. The signal was developed using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Notably, the antibody specifically stained the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0009.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The staining was detected using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Note that this murine CD34 specific antibody stained only the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0010.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse colon using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the colon.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0012.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse heart using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the heart tissue.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0013.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - An intracellular stain was performed on Raw264.7 cells with CD34 Antibody [MEC 14.7] NB600-1071 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488 (SA5-10018, Thermo Fisher).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0015.jpg)